Histone deacetylase inhibitor (HDACi) LBH589 interference with androgen receptor expression transcriptional activity in prostate cancer cells.
2012 | conference abstract. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Histone deacetylase inhibitor (HDACi) LBH589 interference with androgen receptor expression transcriptional activity in prostate cancer cells.
Thelen, P.; Ringert, R.-H. & Strauss, A. (2012)
Journal of Clinical Oncology, 30(15) 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL.
Alexandria: Amer Soc Clinical Oncology.
